A new trading day began on Friday, with Akoya Biosciences Inc (NASDAQ: AKYA) stock price up 2.17% from the previous day of trading, before settling in for the closing price of $2.76. AKYA’s price has ranged from $1.88 to $6.31 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 23.82% over the last five years. Meanwhile, its annual earnings per share averaged 23.47%. With a float of $20.61 million, this company’s outstanding shares have now reached $49.52 million.
The firm has a total of 330 workers. Let’s measure their productivity. In terms of profitability, gross margin is 55.56%, operating margin of -52.17%, and the pretax margin is -66.62%.
Akoya Biosciences Inc (AKYA) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Medical Instruments & Supplies Industry. The insider ownership of Akoya Biosciences Inc is 58.42%, while institutional ownership is 24.59%. The most recent insider transaction that took place on Jun 11 ’24, was worth 15,630. In this transaction President and CEO of this company sold 7,500 shares at a rate of $2.08, taking the stock ownership to the 224,733 shares. Before that another transaction happened on Jun 06 ’24, when Company’s President and CEO sold 7,500 for $2.01, making the entire transaction worth $15,064. This insider now owns 224,733 shares in total.
Akoya Biosciences Inc (AKYA) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.21 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 23.47% per share during the next fiscal year.
Akoya Biosciences Inc (NASDAQ: AKYA) Trading Performance Indicators
Here are Akoya Biosciences Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.85. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.61.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.18, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.62 in one year’s time.
Technical Analysis of Akoya Biosciences Inc (AKYA)
Analysing the last 5-days average volume posted by the [Akoya Biosciences Inc, AKYA], we can find that recorded value of 0.56 million was lower than the volume posted last year of 2.15 million. As of the previous 9 days, the stock’s Stochastic %D was 38.16%. Additionally, its Average True Range was 0.25.
During the past 100 days, Akoya Biosciences Inc’s (AKYA) raw stochastic average was set at 58.04%, which indicates a significant increase from 48.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 89.27% in the past 14 days, which was higher than the 87.14% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.52, while its 200-day Moving Average is $2.74. Now, the first resistance to watch is $2.89. This is followed by the second major resistance level at $2.96. The third major resistance level sits at $3.04. If the price goes on to break the first support level at $2.74, it is likely to go to the next support level at $2.66. Now, if the price goes above the second support level, the third support stands at $2.59.
Akoya Biosciences Inc (NASDAQ: AKYA) Key Stats
With a market capitalization of 139.80 million, the company has a total of 49,573K Shares Outstanding. Currently, annual sales are 96,630 K while annual income is -63,320 K. The company’s previous quarter sales were 18,810 K while its latest quarter income was -10,530 K.
